Tigermed to snag top-end price for $1.4bn Hong Kong IPO

Jonathan Breen

July 31, 2020 08:00 am

Healthcare medical biopharmaceutical investing stock chart background | Kurhan - stock.adobe.com

Hangzhou Tigermed Consulting is set to pocket HK$10.7bn ($1.38bn) from its Hong Kong secondary listing, with solid support from Chinese and global investors driving final pricing to the top of guidance.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

CITIC Securities Credit Suisse UBS Equity China Merchants Bank Co China Bank of America China International Capital Corp Jefferies LLC Hong Kong SAR ICBC Asia Coronavirus Greater China Haitong Securities Northeast Asia Asia Pacific Emerging Markets

JB

Jonathan Breen

Equities editor GlobalCapital Asia